Drugs / Autologous EBV specific CTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02677688 | Jan 2016 → Jul 2021 | systemic lupus erythematosus | Nantes University Hospital | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous EBV specific CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02677688 ↗ |
| Known as | EBV-CTL | “The laboratory isolate T cells specific for EBV (EBV-CTL) of a patient, and stimulate in culture to strengthen them.” NCT02677688 ↗ |
| Action | Restore | “based on the restoration of the patient's immune system, specific EBV” NCT02677688 ↗ |
| Modality | Cell therapy | “based on the principle of cell therapy” NCT02677688 ↗ |
| Route | Intravenous | “by a single intravenous infusion” NCT02677688 ↗ |